Alpha CognitionACOG +0.08%32 Net Margin % is -183.31% as of Mar. 2026. GuruFocus rates ACOG with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 947 Biotechnology companies, Alpha Cognition ranks worse than 62.3% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Alpha Cognition's Net Income for the
three
months ended in Mar. 2026 was $-6.48 Mil. Alpha Cognition's Revenue for the
three
months ended in Mar. 2026 was $3.53 Mil. Therefore, Alpha Cognition's net margin for the quarter that ended in Mar. 2026 was -183.31%.
The historical rank and industry rank for Alpha Cognition's Net Margin % or its related term are showing as below:
ACOG'
s Net Margin % Range Over the Past 10 Years
Min: -232.23 Med: -202.25 Max: -202.25
Current: -232.23
ACOG's Net Margin % is ranked worse than 62.3% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs ACOG: -232.23
Alpha Cognition (NAS:ACOG) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Alpha Cognition Net Margin % Related Terms
Alpha Cognition Net Margin % Historical Data
* Premium members only.
The historical data trend for Alpha Cognition's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alpha Cognition's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Cognition Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Cognition's Net Margin % distribution charts can be found below:
* The bar in red indicates where Alpha Cognition's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Cognition (ACOG) has a Net Margin % of -183.31% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Alpha Cognition and its competitors. According to the industry distribution chart, Alpha Cognition ranks #590 out of 947 companies in the Biotechnology industry, placing it in the top 62.3%.
Is Alpha Cognition's Net Margin % too high?
Alpha Cognition's current Net Margin % is -183.31%. Based on the distribution chart, Alpha Cognition ranks #590 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alpha Cognition has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Cognition's Net Margin % compare to GNLX and VTVT?
According to the Biotechnology industry distribution chart, Alpha Cognition ranks #590 out of 947 companies for Net Margin %. This places Alpha Cognition in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Alpha Cognition and its competitors. Alpha Cognition's current Net Margin % is -183.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Cognition stock overvalued right now?
Alpha Cognition (ACOG) has a current Net Margin % of -183.31%. The current Net Margin % is -183.31%. Alpha Cognition's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Alpha Cognition (ACOG), the current Net Margin % is -183.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
32GF Score
Get the complete analysis for ACOG
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACOG has been successfully added to your 
